Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare - docetaxel anhydrous - concentrate and solvent for solution for infusion - 20 mg - docetaxel anhydrous - docetaxel

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

accord healthcare - docetaxel anhydrous - concentrate and solvent for solution for infusion - 80 mg - docetaxel anhydrous - docetaxel

European Union - English - EMA (European Medicines Agency)

accord healthcare s.l.u. - docetaxel - head and neck neoplasms, carcinoma, non-small-cell lung, adenocarcinoma, prostatic neoplasms, breast neoplasms - antineoplastic agents, - breast cancerdocetaxel accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.for patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.docetaxel accord in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.docetaxel accord monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.docetaxel accord in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer w

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - docetaxel 10 mg/ml - concentrate for infusion - 20 mg/2ml - active: docetaxel 10 mg/ml excipient: citric acid ethanol nitrogen polysorbate 80 - metastatic breast cancer docetaxel sandoz is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel sandoz in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - docetaxel 10 mg/ml - concentrate for infusion - 80 mg/8ml - active: docetaxel 10 mg/ml excipient: citric acid ethanol nitrogen polysorbate 80 - metastatic breast cancer docetaxel sandoz is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel sandoz in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - docetaxel -

New Zealand - English - Medsafe (Medicines Safety Authority)

rex medical ltd - docetaxel trihydrate 135.7mg equivalent to anhydrous docetaxel 120 mg - concentrate for infusion - 120 mg/ml - active: docetaxel trihydrate 135.7mg equivalent to anhydrous docetaxel 120 mg excipient: citric acid polysorbate 80 ethanol water for injection - docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours express her2 and who previously have not received chemotherapy for metastatic disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

rex medical ltd - docetaxel trihydrate 25.177mg equivalent to anhydrous docetaxel 20mg - concentrate for infusion - 20 mg/ml - active: docetaxel trihydrate 25.177mg equivalent to anhydrous docetaxel 20mg excipient: citric acid polysorbate 80 ethanol water for injection - docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours express her2 and who previously have not received chemotherapy for metastatic disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

rex medical ltd - docetaxel trihydrate 100.71mg equivalent to anhydrous docetaxel 80 mg - concentrate for infusion - 80 mg/ml - active: docetaxel trihydrate 100.71mg equivalent to anhydrous docetaxel 80 mg excipient: citric acid polysorbate 80 ethanol water for injection - docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours express her2 and who previously have not received chemotherapy for metastatic disease.

European Union - English - EMA (European Medicines Agency)

mylan s.a.s. - docetaxel - head and neck neoplasms; carcinoma, non-small-cell lung; adenocarcinoma; prostatic neoplasms; breast neoplasms - antineoplastic agents - treatment of breast cancer, special forms of lung cancer (non-small-cell lung cancer), prostate cancer, gastric cancer, or head and neck cancer.